Search all trials

Find therapies in clinical trials near you – page 4

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Registered drugNo placebo

Study of ifinatamab deruxtecan, raludotatug deruxtecan and docetaxel in previously treated stage IV non-small cell lung cancer patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study of telisotuzumab adizutecan with osimertinib as first treatment for adults with advanced or metastatic EGFR-mutated non-small cell lung cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drug

Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Non-small cell lung cancer

Recruiting

InvestigationalNo placebo

Study of WSD0922-FU for Patients with Advanced Non-Small Cell Lung Cancer and C797S Mutation After Osimertinib Treatment

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Registered drugNo placebo

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Nvl-655

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cemiplimab

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study on MaaT033 and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-1/PD-L1 Blockade Due to Antibiotic Use

Registered drugNo placebo

France

Participants:18–64 years
Substances:Bevacizumab

Contact Research Centre

Find therapies in clinical trials near you – page 4

325 trials match your criteria

Non-small cell lung cancer

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Non-small cell lung cancer+1

Study of ifinatamab deruxtecan, raludotatug deruxtecan and docetaxel in previously treated stage IV non-small cell lung cancer patients

Non-small cell lung cancer

Study of telisotuzumab adizutecan with osimertinib as first treatment for adults with advanced or metastatic EGFR-mutated non-small cell lung cancer

Non-small cell lung cancer

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Non-small cell lung cancer

Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

Non-small cell lung cancer

Study of WSD0922-FU for Patients with Advanced Non-Small Cell Lung Cancer and C797S Mutation After Osimertinib Treatment

Non-small cell lung cancer

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Non-small cell lung cancer+2

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Non-small cell lung cancer

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Non-small cell lung cancer

Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

Non-small cell lung cancer

Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer

Study on MaaT033 and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-1/PD-L1 Blockade Due to Antibiotic Use

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.